Shionogi sees COVID pills generating $2 billion in annual revenue after US approval

Japanese company Shionogi & Co believes annual sales of its COVID-19 pill will easily reach $2 billion if it receives U.S.approval, which the company expects to receive in late 2024, its chief executive said.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner